HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Onconova Therapeutics (NASDAQ:ONTX) and maintains an $11 price target.
May 25, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Onconova Therapeutics and maintains an $11 price target.
The Buy rating and maintained $11 price target by HC Wainwright & Co. analyst Joseph Pantginis is a positive signal for Onconova Therapeutics. This reaffirmation of the Buy rating indicates that the analyst continues to have confidence in the company's potential, which could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100